KKR reportedly close to a deal to acquire Integer (ITGR), reports WSJ

Reported-deal stories of this kind, where a major financial sponsor is said to be closing in on a target, follow a well-worn sequence: the target re-rates toward the rumoured consideration while the arb spread stays wide pending confirmation, since a single-sourced report can still fail on price, financing, or process. The relevant track record is twofold. Sponsors of this size have a long history of take-privates in medical technology and outsourced manufacturing, a sector that has repeatedly attracted buyout interest because of its recurring-revenue, contract-based cash flows, and medical device component makers in particular have been taken private before at premiums that reflected their niche customer lock-in. Equally, 'close to a deal' language has historically covered everything from signing within days to talks that stall over diligence, so the distinction between an agreed price and a live process is the operative unknown. What typically resolves the situation is confirmation or denial from the companies, a second-source corroboration from a competing outlet, and any competing bidder interest surfacing, which in past auctions of this type has pushed the consideration higher. Until then the spread and options skew in the target, plus any read-across to sector peers as a re-rating of private-market valuations, are where the signal sits.